Detail akcie Provexis online

Business Summary: Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
Financial Summary: BRIEF: For the six months ended 30 September 2023, Provexis plc revenues increased from L179K to L388K. Net loss increased 71% to L267K. Revenues reflect Fruitflow+omega 3 segment increase of 8% to L89K. Higher net loss reflects Administrative costs - share based payme increase from L11K to L61K (expense), Research and development costs increase of 31% to L140K (expense).